By ELISA, we observed that CLL-MSC release higher amounts of IL-6, IL-8, VEGF and MCP-1. Finally, among 384 genes tested by RQ-PCR (TLDAs, Applied Biosystem) for

9 expanded BM-MSC (5 untreated B-CLL ; 4 normal), we identified 16 statistically up-regulated genes and 41 down-regulated genes. buy CYC202 Up-regulated genes included several growth and angiogenic factors as well as key players of the stroma – tumor cell crosstalk. Most down-regulated genes were involved in differentiation pathways. These results show that CLL-MSC were quantitatively and functionally altered and could be involved in the B-CLL specific stromal cell alterations previously reported (dysregulation of cytokine secretion, angiogenesis, host-tumor relationships). These findings also suggest the possible permissive role of MSC on B-cell clone progression. Poster No. 69 CReMEC Initiative: Creation and Alvocidib cell line Characterization of New in vivo Models of Human Colorectal Cancers Diane Goéré2,6, Pascale Mariani3,6, Marc Pocard4,6, Ludovic Bigot2,6, Fariba Nemati3,6, Denis Lantuas4,6, Loïc Morgand1, Ludovic Lacroix2,6, Sylvia Julien9, Grégoire Prévost9, Patrick Gonin2,6, Virginie Dangles-Marie3,4,6, Alain Pierré8, Alain Bruno8,

Hugues De Thé5,6, Hany Soliman5,6, Ana Merino-Trigo7, Guillaume Lardier7, Hervé Rique7, Brigitte Demers7, Cyril Berthet1, Olivier Duchamp 1 1 Oncodesign, Dijon, France, 2 Institut Gustave Roussy, Villejuif, France, 3 Institut Curie, Paris, France, 4 Hôpital Lariboisière, Paris, France, 5 Hôpital Saint Louis, Paris, France, 6 Canceropole d’Ile de France, Paris, France, 7 Sanofi-aventis, Vitry-sur-Seine, France, 8 Institut de recherche Servier, Croissy sur Seine, France, 9 Ipsen, Paris, find more France New well characterized models representing the heterogeneity of human colorectal cancers (CRC) are needed to develop effective therapeutic agents for that

indication; establishment of such tools will allow a better Interleukin-2 receptor prediction of the clinical outcome, taking into account the diversity of each patient tumor phenotype and genotype. For this purpose and with the financial support of the French Ministry of Industry, we have associated efforts from hospitals, academic groups, biotech and private pharmaceutical companies. From May 2007 to October 2008, 63 surgical specimens [primary tumors (44) and /or metastasis (19)] were collected from CRC patients after obtaining informed consent and confirmation of negative HBV, HCV, and HIVs serologies. Tumor samples were subcutaneously xenografted in Nude and SCID mice. Thirty-five transplantable tumors were passed at least once in animals, indicating a high take rate (55%). The established models are being evaluated for ex vivo and in vivo sensitivities to relevant anticancer drugs (5-FU, oxaliplatin and irinotecan), histological and molecular characteristics.